Literature DB >> 10462537

Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach.

V E Kagan1, J C Yalowich, G G Borisenko, Y Y Tyurina, V A Tyurin, P Thampatty, J P Fabisiak.   

Abstract

Etoposide (VP-16) is extensively used to treat cancer, yet its efficacy is calamitously associated with an increased risk of secondary acute myelogenous leukemia. The mechanisms for the extremely high susceptibility of myeloid stem cells to the leukemogenic effects of etoposide have not been elucidated. We propose a mechanism to account for the etoposide-induced secondary acute myelogenous leukemia and nutritional strategies to prevent this complication of etoposide therapy. We hypothesize that etoposide phenoxyl radicals (etoposide-O(.)) formed from etoposide by myeloperoxidase are responsible for its genotoxic effects in bone marrow progenitor cells, which contain constitutively high myeloperoxidase activity. Here, we used purified human myeloperoxidase, as well as human leukemia HL60 cells with high myeloperoxidase activity and provide evidence of the following. 1) Etoposide undergoes one-electron oxidation to etoposide-O(.) catalyzed by both purified myeloperoxidase and myeloperoxidase activity in HL60 cells; formation of etoposide-O(.)radicals is completely blocked by myeloperoxidase inhibitors, cyanide and azide. 2) Intracellular reductants, GSH and protein sulfhydryls (but not phospholipids), are involved in myeloperoxidase-catalyzed etoposide redox-cycling that oxidizes endogenous thiols; pretreatment of HL60 cells with a maleimide thiol reagent, ThioGlo1, prevents redox-cycling of etoposide-O(.) radicals and permits their direct electron paramagnetic resonance detection in cell homogenates. VP-16 redox-cycling by purified myeloperoxidase (in the presence of GSH) or by myeloperoxidase activity in HL60 cells is accompanied by generation of thiyl radicals, GS(.), determined by HPLC assay of 5, 5-dimethyl-1-pyrroline glytathionyl N-oxide glytathionyl nitrone adducts. 3) Ascorbate directly reduces etoposide-O(.), thus competitively inhibiting etoposide-O(.)-induced thiol oxidation. Ascorbate also diminishes etoposide-induced topo II-DNA complex formation in myeloperoxidase-rich HL60 cells (but not in HL60 cells with myeloperoxidase activity depleted by pretreatment with succinyl acetone). 4) A vitamin E homolog, 2,2,5,7, 8-pentamethyl-6-hydroxychromane, a hindered phenolic compound whose phenoxyl radicals do not oxidize endogenous thiols, effectively competes with etoposide as a substrate for myeloperoxidase, thus preventing etoposide-O(.)-induced redox-cycling. We conclude that nutritional antioxidant strategies can be targeted at minimizing etoposide conversion to etoposide-O(.), thus minimizing the genotoxic effects of the radicals in bone marrow myelogenous progenitor cells, i.e., chemoprevention of etoposide-induced acute myelogenous leukemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10462537     DOI: 10.1124/mol.56.3.494

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

1.  Myeloperoxidase-dependent oxidation of etoposide in human myeloid progenitor CD34+ cells.

Authors:  Irina I Vlasova; Wei-Hong Feng; Julie P Goff; Angela Giorgianni; Duc Do; Susanne M Gollin; Dale W Lewis; Valerian E Kagan; Jack C Yalowich
Journal:  Mol Pharmacol       Date:  2010-11-19       Impact factor: 4.436

2.  Etoposide quinone is a redox-dependent topoisomerase II poison.

Authors:  David A Jacob; Susan L Mercer; Neil Osheroff; Joseph E Deweese
Journal:  Biochemistry       Date:  2011-06-02       Impact factor: 3.162

3.  Lipid antioxidants: free radical scavenging versus regulation of enzymatic lipid peroxidation.

Authors:  Alejandro K Samhan-Arias; Yulia Y Tyurina; Valerian E Kagan
Journal:  J Clin Biochem Nutr       Date:  2010-12-28       Impact factor: 3.114

4.  Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F.

Authors:  Kimberley A O'Hara; Xing Wu; Daywin Patel; Hong Liang; Jack C Yalowich; Nan Chen; Valerie Goodfellow; Otunola Adedayo; Gary I Dmitrienko; Brian B Hasinoff
Journal:  Free Radic Biol Med       Date:  2007-07-13       Impact factor: 7.376

Review 5.  Topoisomerase II and leukemia.

Authors:  Maryjean Pendleton; R Hunter Lindsey; Carolyn A Felix; David Grimwade; Neil Osheroff
Journal:  Ann N Y Acad Sci       Date:  2014-02-03       Impact factor: 5.691

Review 6.  Enzymatic oxidative biodegradation of nanoparticles: Mechanisms, significance and applications.

Authors:  Irina I Vlasova; Alexandr A Kapralov; Zachary P Michael; Seth C Burkert; Michael R Shurin; Alexander Star; Anna A Shvedova; Valerian E Kagan
Journal:  Toxicol Appl Pharmacol       Date:  2016-01-06       Impact factor: 4.219

Review 7.  Deleterious effects of reactive metabolites.

Authors:  Sabry M Attia
Journal:  Oxid Med Cell Longev       Date:  2010 Jul-Aug       Impact factor: 6.543

8.  Etoposide quinone is a covalent poison of human topoisomerase IIβ.

Authors:  Nicholas A Smith; Jo Ann W Byl; Susan L Mercer; Joseph E Deweese; Neil Osheroff
Journal:  Biochemistry       Date:  2014-05-02       Impact factor: 3.162

9.  Curcumin enhances the cytogenotoxic effect of etoposide in leukemia cells through induction of reactive oxygen species.

Authors:  Monika A Papież; Wirginia Krzyściak; Krzysztof Szade; Karolina Bukowska-Straková; Magdalena Kozakowska; Karolina Hajduk; Beata Bystrowska; Jozef Dulak; Alicja Jozkowicz
Journal:  Drug Des Devel Ther       Date:  2016-02-04       Impact factor: 4.162

10.  Role of nitric oxide in the chemistry and anticancer activity of etoposide (VP-16,213).

Authors:  Birandra K Sinha; Suchandra Bhattacharjee; Saurabh Chatterjee; JinJie Jiang; Ann G Motten; Ashutosh Kumar; Michael Graham Espey; Ronald P Mason
Journal:  Chem Res Toxicol       Date:  2013-02-26       Impact factor: 3.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.